Literature DB >> 17197311

Cementless two-stage exchange arthroplasty for infection after total hip arthroplasty.

Bassam A Masri1, Kostas P Panagiotopoulos, Nelson V Greidanus, Donald S Garbuz, Clive P Duncan.   

Abstract

We retrospectively reviewed all patients at one center with an infected total hip arthroplasty treated with 2-stage revision using cementless components for the second stage and the PROSTALAC articulated spacer at the first stage. Twenty-nine patients were reviewed and followed for at least 2 years postoperatively. An isolated Staphylococcus species was cultured in 76% (22/29) of patients. Three (10.3%) of 29 patients had recurrent infection at the site of the prosthesis. One of the 3 patients ultimately underwent a Girdlestone arthroplasty. Another patient was managed with irrigation and debridement, whereas the final patient was treated with intravenous antibiotics alone. Treatment of infection at the site of a hip arthroplasty with 2-stage revision using cementless components and an articulated spacer yields recurrence rates similar to revisions where at least one of the components at the second stage is fixed with antibiotic-loaded cement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17197311     DOI: 10.1016/j.arth.2006.02.156

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  57 in total

1.  An articulating antibiotic spacer controls infection and improves pain and function in a degenerative septic hip.

Authors:  Erin E Fleck; Mark J Spangehl; Venkat R Rapuri; Christopher P Beauchamp
Journal:  Clin Orthop Relat Res       Date:  2011-11       Impact factor: 4.176

Review 2.  Infection in total hip replacement: meta-analysis.

Authors:  Surendra Senthi; Jacob T Munro; Rocco P Pitto
Journal:  Int Orthop       Date:  2010-11-18       Impact factor: 3.075

3.  [Hip joint infections - Results of a questionnaire among 28 university orthopedic departments].

Authors:  K Anagnostakos; D Kohn
Journal:  Orthopade       Date:  2011-09       Impact factor: 1.087

4.  Is two-stage reimplantation effective for virulent pathogenic infection in a periprosthetic hip? A retrospective analysis.

Authors:  Yong-Cheol Yoon; Devendra Lakhotia; Jong-Keon Oh; Jun Gyu Moon; Kumar Prashant; Won Yong Shon
Journal:  World J Orthop       Date:  2015-10-18

5.  Comparison of infection control rates and clinical outcomes in culture-positive and culture-negative infected total-knee arthroplasty.

Authors:  Young-Hoo Kim; Sourabh S Kulkarni; Jang-Won Park; Jun-Shik Kim; Hyun-Keun Oh; Devarshi Rastogi
Journal:  J Orthop       Date:  2015-02-17

6.  Two-stage revision of prosthetic hip joint infections using antibiotic-loaded cement spacers: When is the best time to perform the second stage?

Authors:  Ines Vielgut; Patrick Sadoghi; Matthias Wolf; Lukas Holzer; Andreas Leithner; Gerold Schwantzer; Rudolf Poolman; Bernhard Frankl; Mathias Glehr
Journal:  Int Orthop       Date:  2015-04-14       Impact factor: 3.075

7.  Midterm to long-term followup of staged reimplantation for infected hip arthroplasty.

Authors:  Joaquin Sanchez-Sotelo; Daniel J Berry; Arlen D Hanssen; Miguel E Cabanela
Journal:  Clin Orthop Relat Res       Date:  2008-09-24       Impact factor: 4.176

8.  Prosthetic joint infections.

Authors:  Saima Aslam; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

9.  [Early-onset infection after hemiarthroplasty of the hip: an algorithm for surgical therapy].

Authors:  M Wick; I Maul; G Muhr
Journal:  Orthopade       Date:  2009-07       Impact factor: 1.087

10.  Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty.

Authors:  Ivor Byren; Shruta Rege; Ed Campanaro; Sara Yankelev; Diane Anastasiou; Gennady Kuropatkin; Richard Evans
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.